Swedish medical technology group Vitrolife said on Thursday it would buy reproductive genetic testing services provider Igenomix S.L. in a deal worth 1.25 billion euros ($1.48 billion) on a cash and debt free basis.
Sweden’s Vitrolife to buy Igenomix in EUR 1.25 billion deal
